A number of mAbs and Ab fragments have been developed for preclinical and clinical studies targeting anti-epidermal growth factor receptor (EGFR, known as HER1) in various malignancies (101), HER2 mostly in breast cancer (102), and HER3 in different solid tumors (103–106). Here, EGFR is linked to breast carcinoma.